Characterization of the Immune Microenvironment in Hepatocellular Carcinoma

Mark Yarchoan1, Dongmei Xing1, Lan Luan2

  • 1The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland.

Insights

Hepatocellular carcinoma (HCC) shows increased expression of inhibitory molecules PD-L1 and LAG-3. This suggests that combining PD-L1 and LAG-3 inhibitors may be a promising immunotherapy strategy for HCC treatment.

Area of Science:

  • Oncology
  • Immunology
  • Hepatology

Background:

  • Hepatocellular carcinoma (HCC) frequently develops with chronic liver inflammation.
  • Immunotherapies are emerging as potential treatments for HCC.

Purpose of the Study:

  • To investigate the immune microenvironment in HCC.
  • To analyze the expression of immune checkpoint molecules in HCC tumors.

Main Methods:

  • Immunohistochemistry (IHC) was used to assess CD8, PD-1, LAG-3, CD163, and PD-L1 expression.
  • Analysis was performed on tumor tissue and liver background from 29 HCC cases.

Main Results:

  • CD8 and CD163 expression were reduced in tumor tissues.
  • PD-L1 expression was detected in 83% of HCC cases, and LAG-3 in 65%.
  • Both PD-L1 and LAG-3 expression were elevated in tumors compared to the liver background.

Conclusions:

  • Increased expression of PD-L1 and LAG-3 in HCC suggests their role in T-cell regulation.
  • Combinatorial blockade of PD-L1 and LAG-3 presents a potential therapeutic strategy for HCC.